Bifunctional aptamer-doxorubicin conjugate crosses the blood-brain barrier and selectively delivers its payload to EpCAM-positive tumor cells
journal contributionposted on 13.08.2021, 01:54 authored by J Macdonald, Delphine DenoyerDelphine Denoyer, J Henri, A Jamieson, Ingrid Burvenich, Normand Pouliot, S Shigdar
The prognosis for breast cancer patients diagnosed with brain metastases is poor, with survival time measured merely in months. This can largely be attributed to the limited treatment options capable of reaching the tumor as a result of the highly restrictive blood-brain barrier (BBB). While methods of overcoming this barrier have been developed and employed with current treatment options, the majority are highly invasive and nonspecific, leading to severe neurotoxic side effects. A novel approach to address these issues is the development of therapeutics targeting receptor-mediated transport mechanisms on the BBB endothelial cell membranes. Using this approach, we intercalated doxorubicin (DOX) into a bifunctional aptamer targeting the transferrin receptor on the BBB and epithelial cell adhesion molecule (EpCAM) on metastatic cancer cells. The ability of the DOX-loaded aptamer to transcytose the BBB and selectively deliver the payload to EpCAM-positive tumors was evaluated in an in vitro model and confirmed for the first time in vivo using the MDA-MB-231 breast cancer metastasis model (MDA-MB-231Br). We show that colocalized aptamer and DOX are clearly detectable within the brain lesions 75 min postadministration. Collectively, results from this study demonstrate that through intercalation of a cytotoxic drug into the bifunctional aptamer, a therapeutic delivery vehicle can be developed for specific targeting of EpCAM-positive brain metastases.
JournalNucleic Acid Therapeutics
Pagination12p. (p. 117-128)
PublisherMary Ann Liebert, Inc
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
Science & TechnologyLife Sciences & BiomedicineBiochemistry & Molecular BiologyChemistry, MedicinalMedicine, Research & ExperimentalPharmacology & PharmacyResearch & Experimental Medicineaptamertherapeuticblood brain barriercancerIN-VITROCANCERRECEPTORAGENTSMETASTASESSTABILITYKINETICSOVARIANBlood-Brain BarrierCell Line, TumorAnimalsHumansMiceBreast NeoplasmsBrain NeoplasmsDoxorubicinReceptors, TransferrinAntigens, CDCell ProliferationFemaleAptamers, NucleotideEpithelial Cell Adhesion Molecule